| Literature DB >> 25943629 |
Rudolf Puchner1, Hans Peter Brezinschek2, Josef Fritz3, Manfred Herold4, Monika Mustak5, Thomas Nothnagl6,7, Stephan E Puchner8, Andrea Studnicka-Benke9, Burkhard F Leeb10,11,12.
Abstract
BACKGROUND: A survey was conducted to evaluate whether a steady improvement in the quality of life of Rheumatoid Arthritis (RA) patients as frequently reported in clinical studies, does actually occur. The focus of this study laid on the personal perception of RA patients. How do patients who have been treated along accepted guidelines see the state of their health and their joint pain at different points in time?Entities:
Mesh:
Year: 2015 PMID: 25943629 PMCID: PMC4427952 DOI: 10.1186/s12891-015-0567-5
Source DB: PubMed Journal: BMC Musculoskelet Disord ISSN: 1471-2474 Impact factor: 2.362
Overall patient information and patients’ attitude towards medical care
|
|
|
|---|---|
| Questionnaires completed | 127 (100%) |
|
| |
| Sex | |
| Male | 24 (19%) |
| Female | 103 (81%) |
| Age | |
| Younger than 45 years | 14 (11%) |
| 45 to 60 years | 45 (35%) |
| Older than 60 | 67 (53%) |
| No answer | 1 (1%) |
| First occurrence of RA symptoms | |
| Before the age of 30 | 28 (22%) |
| Between the age of 30 and 40 | 19 (15%) |
| Between the age of 40 and 50 | 28 (22%) |
| Between the age of 50 and 60 | 38 (30%) |
| After the age of 60 | 13 (10%) |
| No answer | 1 (1%) |
| Disease duration1 | |
| Median (IQR) [years] | 8.5 (4–13) |
| ≤3 years | 18 (14%) |
| 4 to 10 years | 30 (24%) |
| ≥11 years | 28 (22%) |
| No answer | 51 (40%) |
| Severity of RA | |
| Mild | 18 (14%) |
| Moderate | 80 (63%) |
| Severe | 26 (21%) |
| No answer | 3 (2%) |
|
| |
| Satisfaction with information received from physician during diagnostic process | |
| Very satisfied | 65 (51%) |
| Satisfied | 30 (24%) |
| Neutral | 17 (13%) |
| Not particularly happy | 9 (7%) |
| Completely dissatisfied | 4 (3%) |
| No answer | 2 (2%) |
| Patient was included in therapeutic decision making by physician | |
| Yes | 105 (83%) |
| No | 16 (13%) |
| Current medications | |
| Methotrexate | 77 (61%) |
| Leflunomide | 13 (10%) |
| Sulphasalazine | 7 (6%) |
| Chloroquine/hydrochloroquine | 4 (3%) |
| Concomitant glucocorticoids | 56 (44%) |
| Biologics | 36 (28%) |
| Alternative or complementary remedies | 17 (13%) |
IQR – interquartile range.
1Disease duration could only be calculated if not only the categories, but also the exact age of diagnosis of disease and current age were provided. Since many patients did not provide this information in the questionnaire, disease duration could not be computed for 51 patients.
Summary of answers to the questionnaire at the three different time-points
|
|
|
|
| |
|---|---|---|---|---|
|
|
|
| ||
|
| ||||
|
| 2.6 ± 0.9 | 2.8 ± 1.1 | 2.8 ± 1.0 | 0.2031 |
|
| 2.7 ± 1.1 | 2.7 ± 1.2 | 2.6 ± 1.0 | 0.6061 |
|
| 2.9 ± 1.1 | 2.8 ± 1.1 | 2.9 ± 1.1 | 0.8871 |
|
| 2.7 ± 1.2 | 2.6 ± 1.2 | 2.8 ± 1.2 | 0.4071 |
|
| ||||
|
| 3.2 ± 1.2 | 2.8 ± 1.2 | 2.7 ± 1.2 | <0.0011 |
|
| ||||
| The pain stresses me | 70.0% (60.9-78.2) | 66.1% (56.9-75.2) | 67.3% (58.4-76.1) | 0.6762 |
| The pain affects my daily life | 70.0% (61.8-78.2) | 49.5% (40.4-58.7) | 46.9% (38.1-55.8) | <0.0012 |
| The illness has psychological repercussions | 51.8% (42.7-60.9) | 42.2% (33.0-51.4) | 42.5% (33.6-51.3) | 0.1232 |
| In spite of my illness, full performance is expected of me | 26.4% (18.2-34.5) | 32.1% (23.9-41.3) | 25.7% (17.7-33.6) | 0.2752 |
| The illness has little or no influence on my life | 25.5% (17.3-33.6) | 44.0% (34.9-53.2) | 36.3% (27.4-45.1) | 0.0042 |
| The illness has had a negative influence on my social status | 22.7% (15.5-30.9) | 20.2% (12.8-27.5) | 26.5% (18.6-34.5) | 0.5662 |
|
| ||||
| Medication makes handling of the illness easier | 90.0% (83.6-95.5) | 93.6% (89.0-97.2) | 83.2% (76.1-89.4) | 0.0392 |
| The illness is simply part of everyday life i.e. I have learned to come to terms with it | 81.8% (74.5-89.1) | 86.2% (79.8-92.7) | 83.2% (76.1-89.4) | 0.8302 |
| I adopted a positive attitude towards the illness | 33.6% (25.5-42.7) | 63.3% (54.1-72.5) | 52.2% (43.4-61.1) | <0.0012 |
| The illness is just a burden | 17.3% (10.0-24.5) | 31.2% (22.9-40.4) | 28.3% (20.4-36.3) | 0.0062 |
|
| ||||
| Independence, i.e. doing things that I want to do | 82.7% (75.5-89.1) | 82.6% (75.2-89.0) | 80.5% (72.6-87.6) | 0.7052 |
| Being active, e.g. sports or going places and doing things | 74.5% (66.4-82.7) | 76.1% (67.9-83.5) | 80.5% (73.5-87.6) | 0.8092 |
| Social activity, e.g. meeting friends | 72.7% (64.5-80.9) | 78.9% (71.6-86.2) | 83.2% (76.1-89.4) | 0.2002 |
| Good physical well-being, e.g. being pain-free and mobile | 61.8% (52.7-70.9) | 82.6% (75.2-89.0) | 78.8% (71.7-85.8) | 0.0012 |
| Other | 2.7% (0.0-6.4) | 3.7% (0.9-7.3) | 3.5% (0.9-7.1) | 1.0002 |
|
| ||||
| Generally optimistic | 54.5% (45.5-63.6) | 46.6% (36.9-56.3) | 52.4% (42.7-62.1) | 0.1791 |
| Neutral | 40.0% (30.9-49.1) | 43.7% (34.0-53.4) | 35.0 (26.2-44.7)% | |
| Generally pessimistic | 5.5% (1.8-10.0) | 9.7% (3.9-15.5) | 12.6% (6.8-19.4) | |
N – number of answered questionnaires; SD – standard deviation; CI – confidence interval; percentages (pct.) are based on N; CIs were obtained by bootstrapping method based on 10000 replications; NC – not captured.
1p-value of Friedman test; 2p-value of Cochran’s Q test.
Intra-subject correlation and level of agreement at different times
|
|
|
| |
|---|---|---|---|
|
| |||
|
| 0.371 | 0.481 | 0.471 |
|
| 0.391 | 0.391 | 0.401 |
|
| 0.481 | 0.371 | 0.401 |
|
| 0.351 | 0.401 | 0.461 |
|
| |||
|
| 0.471 | 0.411 | 0.561 |
|
| |||
| The pain stresses me | 0.452 | 0.372 | 0.392 |
| The pain affects my daily life | 0.482 | 0.192 | 0.292 |
| The illness has psychological repercussions | 0.312 | 0.422 | 0.332 |
| In spite of my illness, full performance is expected of me | 0.412 | 0.392 | 0.352 |
| The illness has little or no influence on my life | 0.132 | 0.122 | 0.372 |
| The illness has had a negative influence on my social status | 0.282 | 0.252 | 0.262 |
|
| |||
| Medication makes handling of the illness easier | 0.192 | 0.232 | 0.082 |
| The illness is simply part of everyday life i.e. I have learned to come to terms with it | 0.162 | 0.362 | 0.252 |
| I adopted a positive attitude towards the illness | 0.232 | 0.082 | 0.112 |
| The illness is just a burden | 0.322 | 0.262 | 0.372 |
|
| |||
| Independence, i.e. doing things that I want to do | 0.122 | −0.042 | 0.102 |
| Being active, e.g. sports or going places and doing things | 0.112 | 0.192 | 0.052 |
| Social activity, e.g. meeting friends | 0.142 | 0.112 | 0.142 |
| Good physical well-being, e.g. being pain-free and mobile | 0.032 | −0.042 | 0.142 |
| Other | 0.562 | −0.032 | −0.042 |
|
| 0.551 | 0.311 | 0.531 |
1Intraclass correlation coefficient (ICC) for one-way random single measures; 2Cohen’s Kappa.
Figure 1“How would you describe your current state of health?” (Individual ratings).
Figure 2“How is your joint pain today?” (Individual ratings).
Subgroup analyses for sex and treatment with biologics
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|
|
|
|
| ||||
|
| ||||||
|
| ||||||
| Men | 2.5 ± 0.8 | 2.6 ± 1.1 | 2.7 ± 1.1 | 0.29 | 0.44 | 0.56 |
| Women | 2.6 ± 0.9 | 2.8 ± 1.1 | 2.8 ± 1.0 | 0.39 | 0.49 | 0.44 |
| Biologics as current medication | 2.6 ± 0.9 | 2.7 ± 1.1 | 2.7 ± 1.1 | 0.51 | 0.57 | 0.54 |
| No biologics as current medication | 2.6 ± 0.9 | 2.9 ± 1.1 | 2.8 ± 1.0 | 0.30 | 0.41 | 0.43 |
| Disease duration ≤3 years | 2.8 ± 0.8 | 2.8 ± 1.1 | 2.7 ± 0.8 | 0.45 | 0.50 | 0.50 |
| Disease duration 4 to 10 years | 2.7 ± 0.9 | 2.9 ± 1.2 | 3.0 ± 1.2 | 0.57 | 0.47 | 0.58 |
| Disease duration ≥11 years | 2.4 ± 1.0 | 2.8 ± 1.1 | 2.9 ± 0.9 | 0.41 | 0.60 | 0.32 |
|
| ||||||
| Men | 2.7 ± 1.0 | 2.6 ± 1.2 | 2.6 ± 0.9 | 0.63 | 0.32 | 0.48 |
| Women | 2.7 ± 1.1 | 2.7 ± 1.2 | 2.7 ± 1.1 | 0.35 | 0.40 | 0.39 |
| Biologics as current medication | 2.5 ± 1.0 | 2.6 ± 1.2 | 2.7 ± 1.2 | 0.32 | 0.29 | 0.38 |
| No biologics as current medication | 2.8 ± 1.2 | 2.7 ± 1.1 | 2.6 ± 0.9 | 0.42 | 0.45 | 0.42 |
| Disease duration ≤3 years | 2.8 ± 1.1 | 2.5 ± 1.1 | 2.6 ± 0.9 | 0.18 | 0.47 | 0.46 |
| Disease duration 4 to 10 years | 2.8 ± 0.9 | 2.8 ± 1.2 | 2.7 ± 1.0 | 0.57 | 0.53 | 0.29 |
| Disease duration ≥11 years | 2.6 ± 1.3 | 2.7 ± 1.1 | 2.8 ± 1.1 | 0.59 | 0.34 | 0.28 |
|
| ||||||
| Men | 3.0 ± 1.0 | 2.7 ± 1.0 | 2.9 ± 1.2 | 0.28 | 0.20 | 0.25 |
| Women | 2.9 ± 1.2 | 2.8 ± 1.1 | 2.8 ± 1.1 | 0.52 | 0.42 | 0.42 |
| Biologics as current medication | 2.7 ± 1.0 | 2.8 ± 1.2 | 2.9 ± 1.2 | 0.69 | 0.44 | 0.57 |
| No biologics as current medication | 3.0 ± 1.2 | 2.8 ± 1.1 | 2.9 ± 1.1 | 0.39 | 0.34 | 0.31 |
| Disease duration ≤3 years | 2.9 ± 1.2 | 2.6 ± 1.3 | 2.8 ± 1.2 | 0.25 | 0.23 | 0.64 |
| Disease duration 4 to 10 years | 2.7 ± 1.0 | 3.0 ± 1.2 | 3.0 ± 1.1 | 0.60 | 0.50 | 0.45 |
| Disease duration ≥11 years | 2.9 ± 1.3 | 2.7 ± 1.2 | 3.0 ± 1.0 | 0.48 | 0.20 | 0.22 |
|
| ||||||
| Men | 2.7 ± 1.2 | 2.6 ± 1.3 | 2.7 ± 1.4 | 0.24 | 0.46 | 0.65 |
| Women | 2.7 ± 1.2 | 2.7 ± 1.1 | 2.8 ± 1.2 | 0.38 | 0.38 | 0.41 |
| Biologics as current medication | 2.4 ± 1.0 | 2.7 ± 1.2 | 2.7 ± 1.3 | 0.52 | 0.41 | 0.48 |
| No biologics as current medication | 2.8 ± 1.3 | 2.6 ± 1.2 | 2.8 ± 1.2 | 0.28 | 0.39 | 0.46 |
| Disease duration ≤3 years | 2.6 ± 1.4 | 2.5 ± 1.2 | 2.5 ± 1.3 | 0.46 | 0.16 | 0.39 |
| Disease duration 4 to 10 years | 2.5 ± 1.0 | 2.9 ± 1.3 | 2.8 ± 1.2 | 0.47 | 0.47 | 0.73 |
| Disease duration ≥11 years | 2.9 ± 1.4 | 2.6 ± 1.1 | 2.9 ± 1.3 | 0.25 | 0.51 | 0.24 |
|
| ||||||
|
| ||||||
| Men | 3.0 ± 1.3 | 2.8 ± 1.5 | 2.6 ± 1.2 | 0.33 | 0.39 | 0.58 |
| Women | 3.2 ± 1.2 | 2.8 ± 1.2 | 2.6 ± 1.2 | 0.51 | 0.42 | 0.56 |
| Biologics as current medication | 3.1 ± 1.2 | 2.6 ± 1.2 | 2.7 ± 1.3 | 0.39 | 0.37 | 0.64 |
| No biologics as current medication | 3.2 ± 1.2 | 2.8 ± 1.3 | 2.7 ± 1.1 | 0.51 | 0.44 | 0.52 |
| Disease duration ≤3 years | 3.1 ± 1.1 | 2.3 ± 1.1 | 2.5 ± 1.0 | 0.03 | 0.07 | 0.21 |
| Disease duration 4 to 10 years | 3.1 ± 1.0 | 3.0 ± 1.3 | 2.8 ± 1.3 | 0.52 | 0.49 | 0.56 |
| Disease duration ≥11 years | 3.2 ± 1.3 | 2.6 ± 1.2 | 2.7 ± 1.2 | 0.48 | 0.53 | 0.62 |
SD – standard deviation; ICC - Intraclass correlation coefficient for one-way random single measures.
No statistically significant differences between men and women, between use of biologics and no biologics, and between disease duration subgroups were observed.